L&L BIOPHARMA

Founded in 2015, L&L Biopharmaceutical Co., Ltd., Shanghai (L&L Biopharma) is a high-tech company specializing in the research and development of innovative biopharmaceuticals, with a focus on the bi-/multi-specific antibodies for tumor immunotherapy. L&L Biopharma has established state-of-the-art bi-/multi-specific antibody technology platforms, including hybridoma technology platform, computer-aided humanization technology platform, cell line engineering platform, and a proprietary core platform - Sequence-Specific IgG-like Bispecific Antibody (SBody) platform. The company is dedicated to addressing the clinical needs of cancer patients with primary or acquired resistance to anti-PD-1/PD-L1 therapies.

Also known as: L&L

Primary location: Shanghai China